In comparison to the 5-year-long conventional diagnosis and treatment with limited success, the current study derived LQTS patient-specific, KCNQ1 & TRPM4 dual mutation cardiomyocytes to act as a disease model for drug screening. Here, TRPM4 is linked to familial long QT syndrome.